Company news

Amplia Therapeutics Ltd. news in 2025

Amplia Therapeutics Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

December 23, 2025

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

December 19, 2025

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

December 12, 2025

Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th

December 8, 2025

Key Narmafotinib Patent Granted in the U.S.

December 3, 2025

Half Yearly Report and Accounts

November 27, 2025

Positive Response from US FDA to Amplia's Type D Meeting

November 19, 2025

Amplia Receives R&D Tax Rebate Totalling $3.77 Million

October 27, 2025

First patient dosed in new pancreatic cancer trial

September 3, 2025

Amplia Share Purchase Plan Raises $2.65 Million

August 25, 2025

Positive ACCENT Trial Topline Data Released

August 5, 2025

Capital Raising Presentation

July 23, 2025

Amplia announces A$25m Placement and Launches A$2.5m SPP

July 23, 2025

Second Complete Response in ACCENT Pancreatic Cancer Trial

June 18, 2025

Pathological complete response recorded in patient from ACCENT cancer trial

June 16, 2025

Pathological Complete Response in Pancreatic Cancer Trial

June 15, 2025

Preliminary Final Report and Annual Report YE 31 March 2025

May 30, 2025

ACCENT Trial Achieves Superiority over Chemotherapy Alone

May 14, 2025

Completion of Recruitment of ACCENT Trial

January 30, 2025

Decks in 2025